STOCK TITAN
  1. Home
  2. Sec-filings
  3. RVMD
  4. [Form 4] Revolution Medicines, Inc. Insider Trading Activity

[Form 4] Revolution Medicines, Inc. Insider Trading Activity

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Revolution Medicines (RVMD) President and CEO Mark A. Goldsmith reported an option exercise and stock sale. On 11/18/2025, he exercised a stock option for 20,000 shares of common stock at an exercise price of $4.09 per share, then sold 20,000 shares of common stock in open market transactions at a weighted average price of $70.3793 per share.

After these transactions, he directly beneficially owned 247,863 shares of common stock, which includes 193,475 restricted stock unitsRule 10b5-1 trading plan adopted on December 19, 2024, indicating the trades were pre-arranged under that plan.

Positive

  • None.

Negative

  • None.
Insider GOLDSMITH MARK A
Role See Remarks
Sold 20,000 shs ($1.41M)
Approx. gross sale proceeds $1.41M
Approx. exercise cost $82K
Approx. pre-tax spread $1.33M
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 20,000 $0.00 $0.00
Exercise Common Stock 20,000 $4.09 $82K
Sale Common Stock 20,000 $70.3793 $1.41M
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 137,708 shares (Direct); Common Stock — 247,863 shares (Direct); Common Stock — 710,898 shares (Indirect, Trust)
Footnotes (8)
  1. F1. Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024.
  2. F2. Includes 193,475 restricted stock units.
  3. F3. This transaction was executed in multiple trades at prices ranging from $70.00 to $70.89. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. F4. Held by Jonathan Goldsmith Revocable Trust.
  5. F5. Reflects the transfer of 15,926 shares.
  6. F6. Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.
  7. F7. Held by Rebecca Goldsmith Revocable Trust.
  8. F8. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GOLDSMITH MARK A
(Last) (First) (Middle)
C/O REVOLUTION MEDICINES, INC.
700 SAGINAW DRIVE
(Street)
REDWOOD CITY CA 94063
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/18/2025 M(1) 20,000 A $4.09 267,863(2) D
Common Stock 11/18/2025 S(1) 20,000 D $70.3793(3) 247,863(2) D
Common Stock 70,424 I Trust(4)
Common Stock 0(5) I Trust(6)
Common Stock 70,424(5) I Trust(7)
Common Stock 570,050 I Trust(8)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $4.09 11/18/2025 M(1) 20,000 03/13/2023 03/12/2029 Common Stock 20,000 $0 137,708 D
Explanation of Responses:
1. Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024.
2. Includes 193,475 restricted stock units.
3. This transaction was executed in multiple trades at prices ranging from $70.00 to $70.89. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. Held by Jonathan Goldsmith Revocable Trust.
5. Reflects the transfer of 15,926 shares.
6. Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.
7. Held by Rebecca Goldsmith Revocable Trust.
8. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
Remarks:
President and Chief Executive Officer
/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith 11/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR